European Parliament building in Strasbourg — EU CBD Novel Food regulation 2026
News

EU Rejects 6 More CBD Novel Food Applications — What It Means for the €2.6B European CBD Market

Six more CBD novel food applications were rejected by EU regulators in April 2026, bringing the total to 12 rejections this year. With EFSA setting a provisional safe intake limit of just 0.0275 mg/kg/day, we break down what this means for the €2.6 billion European CBD industry, consumers, and businesses.

By The Green Treasure9 min read
Sponsored
Cannabis SEO Agency — We Grow Your Rankings
Starter from €800/mo · Free audit included
Explore Agency Services →

The Germany's cannabis law anniversary reportan EFSA's 2mg CBD limit ruling industry is facing a watershed moment. In April 2026, the European Food Safety Authority (EFSA) rejected six more cannabidiol (CBD) novel food applications, bringing the total number of rejections in 2026 alone to twelve. For a market valued at €2.6 billion and growing, these decisions send a clear and sobering message: the path to legal CBD food products in the European Union remains extraordinarily difficult — and is becoming more so by the month. CBD brands navigating the evolving regulatory landscape need strong organic visibility. Our cannabis SEO agency specializes in compliant, high-performing content strategies.

Eu Cbd Novel Food Rejected 2026 — editorial scene
Eu Cbd Novel Food Rejected 2026 — editorial scene
++
SponsoredSponsored — Nordkraut

Frequently Asked Questions

The EU Novel Food Regulation requires pre-market authorization for foods and supplements not widely consumed before May 1997. The European Commission classified isolated CBD extracts as Novel Foods in 2019, requiring expensive approval processes for CBD products. For a broader overview of CBD in Europe, see our CBD oil guide.
The European Food Safety Authority (EFSA) rejected applications primarily due to insufficient safety data on chronic CBD consumption, reproductive toxicity concerns at higher doses, and data gaps in submitted dossiers. Applicants have option to resubmit with additional data. For the German regulatory context, see our Germany cannabis reform two-year review.
Yes — CBD products remain available throughout Europe. The rejections affect specific applications, not the entire market. Low-dose CBD products and hemp-derived extracts with broad cannabinoid profiles continue to be sold throughout the EU. For legal status by country, check our cannabis legality guide.
The regulatory uncertainty continues for CBD isolate-based products. Full-spectrum and broad-spectrum hemp extracts may face different regulatory treatment. Consumers should buy from established brands that provide full third-party lab testing. For a primer on CBD product types, read our CBD oil guide.
Primarily isolated CBD extracts and high-dose CBD products intended for oral consumption. Hemp seed oil (which contains minimal CBD) and topical CBD products are generally outside Novel Food scope. The situation varies by member state. Understanding the difference between CBD and THC is important for navigating these regulations.

Share this article

The Green Treasure Editorial Team

Written by

The Green Treasure Editorial Team

Independent cannabis journalism backed by science. We cover terpenes, vaporizers, edibles, growing and health.

About Us|
Follow us soon
🌿Newsletter

Stay in the green loop

Expert guides, terpene science, growing tips, and gear reviews — delivered to your inbox. No spam, ever.

No spam. Unsubscribe anytime.

Related Articles

EFSA CBD 2mg limit 2026 — legal documents and cannabis leaf on EU regulatory desk
News

EFSA Sets 2mg/Day CBD Safety Limit — Most EU Products Now Effectively Illegal

EFSA has set a provisional safe daily intake of just 2mg of CBD per day — leaving virtually every CBD supplement on the EU market in legally uncertain territory. We explain what the limit means, why Germany is enforcing hardest, and how the EU diverges from UK and US rules.

7 min read
Germany Cannabis Act two years evaluation — Ekocan report, no harm found
News

Germany's Cannabis Act 2 Years On: No Harm Found, Critics Contradicted

Germany's mandatory Ekocan evaluation of the Cannabis Act found zero evidence of increased youth consumption or societal harm — directly contradicting opponents' predictions while revealing a medical market that more than doubled in 2025.

7 min read
germany cannabis reform criticism 2026 hero
News

Germany Cannabis Reform: What the Critics Get Right (and Wrong)

Two years in, Germany's cannabis reform has delivered real results and real failures. An honest assessment of the most credible criticisms — and where they miss the mark.

8 min read